Brokers Name 3 ASX Shares to Buy Now 10 May 2024

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

The Motley FoolMay 10 12:25

Why Cettire, De Grey Mining, Life360, and Neuren Shares Are Falling Today

The S&P/ASX 200 Index (ASX: XJO) has returned to form on Friday. In afternoon trade, the benchmark index is up 0.5% to 7,759.5 points.

The Motley FoolMay 10 11:19

Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk

0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not

WSJMay 10 08:12

Neuren Pharmaceuticals Price Target Cut 1.9% to A$26.50/Share by Bell Potter

Neuren Pharmaceuticals Price Target Cut 1.9% to A$26.50/Share by Bell Potter

Dow JonesMay 10 06:23

Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million

Neuren Pharmaceuticals (ASX:NEU) partner Acadia Pharmaceuticals (NASDAQ:ACAD) posted Q1 net sales of its DAYBUE treatment in the US of $75.9 million, below its guidance of $76 million to $82 million,

MT NewswiresMay 10 05:24

Why This High-flying ASX 200 Healthcare Stock Just Crashed 11%

It was the ASX 200 healthcare stock of the year in 2023, with its share price catapulting 214% in just 12 months.

The Motley FoolMay 9 11:49